Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration
about
New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale.Teaching 'old' polymyxins new tricks: new-generation lipopeptides targeting gram-negative 'superbugs'.Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models.Colistin-induced nephrotoxicity in mice involves the mitochondrial, death receptor, and endoplasmic reticulum pathways.Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 2. ColistinA novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membranePharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model.Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes.'Old' antibiotics for emerging multidrug-resistant bacteriaComparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients.Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa.Colistin pharmacokinetics in burn patients during continuous venovenous hemofiltration.Lycopene attenuates colistin-induced nephrotoxicity in mice via activation of the Nrf2/HO-1 pathway.Colistin and polymyxin B: peas in a pod, or chalk and cheese?Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii.Significant accumulation of polymyxin in single renal tubular cells: a medicinal chemistry and triple correlative microscopy approach.Imaging the distribution of polymyxins in the kidneyPopulation pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patientsMajor pathways of polymyxin-induced apoptosis in rat kidney proximal tubular cells.Development and validation of an in vitro pharmacokinetic/pharmacodynamic model to test the antibacterial efficacy of antibiotic polymer conjugates.Melatonin attenuates colistin-induced nephrotoxicity in rats.Dosing of colistin-back to basic PK/PD.Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula.Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosingSynergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model.Preliminary clinical study of the effect of ascorbic acid on colistin-associated nephrotoxicityA 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokineticsColistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.Structure-activity relationships for the binding of polymyxins with human α-1-acid glycoproteinThe combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic modelCellular Uptake and Localization of Polymyxins in Renal Tubular Cells Using Rationally Designed Fluorescent Probes.Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?Human oligopeptide transporter 2 (PEPT2) mediates cellular uptake of polymyxins.Nephrotoxicity and efficacy assessment of polymyxin use in 92 transplant patientsPopulation pharmacokinetic analysis of colistin in burn patients.Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model.Polymyxin B Induces Apoptosis in Kidney Proximal Tubular Cells.Antimicrobial Activity and Toxicity of the Major Lipopeptide Components of Polymyxin B and Colistin: Last-line Antibiotics against Multidrug-Resistant Gram-negative BacteriaPharmacokinetics of four different brands of colistimethate and formed colistin in rats.
P2860
Q30856181-DF3AEBB1-112D-49F4-B17F-C36A3683E82BQ33662378-934A0957-2F31-43B1-A0EE-69569936CDEAQ33676366-170406BB-9D69-486A-9AB8-27D041604327Q33798324-4200D167-4816-4235-A195-765066910F1FQ33798554-0CB25E68-FF00-4CAA-A276-A51A34377AC8Q34045186-9E04ED3F-649E-453C-A591-F72327CB2273Q34108660-8D8D2D0A-35FE-4D73-9548-76369292133DQ34552966-E80561BF-B797-454B-82E9-7991CAE63439Q34565772-ACAE0AD4-0142-467B-8D24-20864085CEC3Q34597749-A11F263D-C3CC-43E2-B019-31644A7E808DQ34680516-A6C42BD3-D20D-4961-9060-4E47F1471855Q34922728-1B5BCAD9-502A-426A-8243-2B314669A45CQ34922961-44C36F39-941B-4BB5-A617-1982B230400DQ35008357-0914A245-8846-4177-9DE4-C868AC100839Q35023321-60C7D624-6080-4D1E-8257-C95FA283A07CQ35054109-A846C1B5-9ED0-4E54-A4B0-F57A0160E765Q35056878-4E636BC3-D7E9-4CBA-8E19-2736A6BF312AQ35065863-40ECDD3D-BB77-4BAF-8EEC-3FB13DFA2DCDQ35168993-68B6174B-7996-40C4-954A-83457A4682C0Q35169065-90C70B02-53D2-4BDE-984C-6C79A94D826FQ35191353-A667B0D2-A50F-403E-9D49-2F63316C7659Q35242165-204C42EB-9AB1-4BD4-8811-FE918660A506Q35364351-A39A01CC-5B0D-40C8-8C6C-2E4A307A398AQ35541277-5AA4BB86-5CD0-4A14-B7A9-C5ACC1507398Q35598403-279E3C1C-C59B-439B-96AC-BBD10251567EQ35607925-BDCEFF21-AEAE-4B72-AAAA-DC3E6259554FQ35617587-BA713DEF-D7C0-4679-8D6B-52C01CBF5C81Q35662008-E56BB997-C817-4AFC-A313-DF742E46C77CQ36095874-2999EF0E-1172-4B40-B22A-4AC4406250ADQ36252997-EAF21501-3039-43BE-910E-6F5B3C165177Q36276852-C87C5CD2-5B10-4872-B4AD-8AEA45E5E1B1Q36290642-8B1A9B56-3E01-44A8-B21E-F16E7C9FCBDAQ36335694-089BA8B0-7AEE-436B-886F-EA78E0888541Q36455352-266E1B11-25F0-4D14-8714-0F3B69DAD321Q36667079-D11892B0-7B7A-4F86-B5D2-A19D944306B7Q36785854-9381074F-176E-4F32-91D5-81D2E6457C84Q37036489-75CC6709-01AB-47F2-948E-FD2FCB51197BQ37124019-3BAD498C-83A4-4B44-A60E-BB25C706A814Q37165591-60491BE0-2871-4EAE-951A-F29958D3D6FFQ37169946-B75EBAB9-7FD9-4719-8A50-554232A2B4D8
P2860
Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Use of high-performance liquid ...... ing intravenous administration
@ast
Use of high-performance liquid ...... ing intravenous administration
@en
Use of high-performance liquid ...... ing intravenous administration
@nl
type
label
Use of high-performance liquid ...... ing intravenous administration
@ast
Use of high-performance liquid ...... ing intravenous administration
@en
Use of high-performance liquid ...... ing intravenous administration
@nl
prefLabel
Use of high-performance liquid ...... ing intravenous administration
@ast
Use of high-performance liquid ...... ing intravenous administration
@en
Use of high-performance liquid ...... ing intravenous administration
@nl
P2093
P2860
P50
P1476
Use of high-performance liquid ...... ing intravenous administration
@en
P2093
John D Turnidge
Kingsley Coulthard
Timothy C Smeaton
P2860
P304
P356
10.1128/AAC.47.5.1766-1770.2003
P407
P577
2003-05-01T00:00:00Z